{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-037346","form_type":"8-K","ticker":"DCGO","cik":"0001822359","company_name":"DocGo Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.875965+00:00","generated_at":"2026-06-15T14:07:45.735762+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"DocGo Q1 revenue $113M, net loss $3.9M; reaffirms FY2023 guidance","bullets":["Q1 revenue $113.0M, down 4.2% YoY; ex-COVID testing, revenue up 40.2%.","Net loss of $3.9M vs. net income of $9.4M in Q1 2022; Adj. EBITDA $5.6M.","Gross margin 28.1% vs 33.9% YoY; cites startup costs from new project, expects recovery.","Backlog rose to $205M from $180M; active RFPs doubled to ~$1.5B lifetime value.","Reiterates FY2023 revenue guidance $500-$510M and Adj. EBITDA $45-$50M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-037346","json":"https://secwatch.observer/filing/0001213900-23-037346.json","markdown":"https://secwatch.observer/filing/0001213900-23-037346.md","text":"https://secwatch.observer/filing/0001213900-23-037346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822359/000121390023037346/0001213900-23-037346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822359/000121390023037346/ea178143-8k_docgo.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T14:07:45.735762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b087dfafb3e2e4335753157ae808d2d4ec121bd","claim":"DocGo Inc. reported quarter ended March 31, 2023 results: revenue $113.0 million, net income Net loss was $3.9 million. Guidance reaffirmed.","evidence_excerpt":"today announced financial and operating results for the quarter ended March 31, 2023. Q1 2023 Financial Highlights ● Total revenue, net for the first quarter of 2023 was $113.0 million, compared to $117.9 million in the first quarter of 2022, a decrease of 4.2%. Excluding mass COVID testing revenue from both periods, revenue increased 40.2% from year ago","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822359/000121390023037346/0001213900-23-037346-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2023"},{"label":"Revenue","value":"$113.0 million"},{"label":"Net income","value":"Net loss was $3.9 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}